AstraZeneca COVID-19 Vaccine Linked to Rare Thrombosis, Thrombocytopenia Events
The newest research of rare adverse events among patients administered the vaccine highlights that venous or arterial thrombosis can develop in unexpected regions, including the brain or abdomen, 5-20 days after administration.
How Do COVID-19 Vaccines Benefit Transplant Recipients?
A new commentary from experts highlight the evolving understanding of antibody response in vaccinated transplant patients.
Solutions to COVID-19 Vaccine Hesistancy
An expert stresses the need to consider individuals' worry over information—and even their history with systemic biases.
Building COVID-19 Vaccine Trust is a Two-Way Street
Vaccine access and new cases are both increasing. An expert discusses earning trust in at-risk communities.
Pfizer-BioNTech COVID-19 Vaccine is 91% Effective at 6 Months
The companies are now seeking a Biologics License Application with the FDA, which would allow it to become more greatly available for adults in the US.
Pfizer-BioNTech Reports 100% Efficacy in Adolescents Given COVID-19 Vaccine
The pivotal phase 3 data, based off 18 reported cases among placebo patients, includes the companies' intention to request authorization for adolescents aged 12-15 years old.
Biden, CDC Urge Legislators to Maintain COVID-19 Mask Mandates Amid Rising Cases
Cases have increased by 16%, while 50 million have now been fully vaccinated. Federal leadership is asking Americans to hold on longer.
NIAID, Review Board Challenges New AstraZeneca COVID-19 Vaccine Data
A statement hours after the company reported promising interim phase 3 data stated the Data Safety and Monitoring Board believes they included outdated data “which may have provided an incomplete view of the efficacy data.”
AstraZeneca Reports 79% COVID-19 Vaccine Efficacy, Will Submit for EUA
After a year of setbacks, AZD1222 has been associated with 100% prevention of severe COVID-19 in US trial participants. Could emergency authorization come soon?
HTI Vaccine Regimen Shows Immunogenicity in HIV Patients
Phase 1/2 trial results showed the immunomodulary vaccine regimen could induce significant T-cell response in patients with HIV.
Pfizer and BioNTech Report 97% COVID-19 Vaccine Efficacy in Israel Population
The data additionally show a 94% prevention against asymptomatic SARS-CoV-2 infection, at a time when the country's dominant strain was the B.1.1.7 variant.
US Has Millions of AstraZeneca COVID-19 Vaccines Available
Though the product is authorized more than 70 countries, there is currently no reported US trial data, nor application for authorization to the FDA.
Biden Announces Purchase of 100 Million Janssen COVID-19 Vaccine Doses
The acquisition of the Johnson & Johnson pharmaceutical company's vaccine would likely be completed in the latter half of this year.
Why COVID-19 Booster Vaccines May Be Warranted This Year
A UK health authority representative discussed the possibility of a fall season booster to prevent another winter surge of cases.
Biden: US Will Have Enough COVID-19 Vaccines for All Adults by End of May
The statement comes on the same day as a rare production agreement between pharmaceutical rivals, and Texas' announced lift of spread mitigation measures.
Pfizer-BioNTech Evaluating Third COVID-19 Vaccine Dose for Variants
The new trial comes at a time when the FDA has provided guidance on navigating immunogenicity trials for vaccines designed against more transmissible SARS-CoV-2 strains.
Israel Data Show Real-World Efficacy with Pfizer COVID-19 Vaccine
A massive assessment of a quickly vaccinated population shows the mRNA vaccine provides greater protection over time.
FDA Grants Priority Review to Possibly First TBE Vaccine from Pfizer
TicoVac will be decided on for both pediatric and adult people at risk of the tick-borne virus in August.
FDA Provides Guidance for Vaccine Assessment Against COVID-19 Variants
The new advisory is informed by currently-understood effect of authorized vaccines against circulating SARS-CoV-2—which show benefit nonetheless.
Pfizer Could More Than Double Its Weekly COVID-19 Vaccine Production in March
The news comes on the same day as new data showing the vaccine's efficacy as a single-dose prophylactic, as well as the company's application for eased storage standards for US supplies.
From Single-Use to Multi-Use: A Brief Review of N95 Respirator Decontamination Strategies
This indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.
AstraZeneca Vaccine Preprint Does Not Bode Well for COVID-19 Variant Response
New South Africa-based data show not only lessened protection versus the region's dominant variant, but a reduced vaccine-induced antibody neutralization.
Getting Help from HAL: Applying Machine Learning to Predict Antibiotic Resistance
A pair of experts assess literature on the means of interpreting hospitalized patient antibiotic resistance through machine learning.
South Africa Pauses AstraZeneca COVID-19 Vaccine Rollout
The two-dose vaccine's ineffective prevention of the more transmissible virus variant led to official seeking better options—and broader outcomes.
Janssen Submits One-Dose COVID-19 Vaccine to FDA for Emergency Authorization
Pending advisory committee support and granted authorization, the adenovirus vaccine could become the first single-shot option in the US.
Russia COVID-19 Vaccine Reports 91.6% Efficacy, Prevention of Severe Disease
New preliminary phase 3 data show the two-dose vaccine may even hold benefit for single-dose use.
Newborns From Infected Mothers Have SARS-CoV-2 Antibodies
Cohort data shows 87% of infants born to mothers with asymptomatic or symptomatic COVID-19 have developed antibodies at birth.
COVID-19 Vaccine Updates for February 2021
A video breakdown of the past week's developments and news in leading vaccine candidates.
Preprint Data: Pfizer Vaccine Shows Reduced COVID-19 Risk After 2 Weeks Administration
The to-be-reviewed assessment of real-world vaccine recipients suggests 51% greater efficacy with BNT162b2 after 13-24 days.
Pfizer Will Count COVID-19 Vaccine Vial Overfills Toward US Quota of Doses
In a move being ill-received by clinicians, the COVID-19 vaccine producer is lessening the count of vials being supplied to the government through July.
2 Clarke Drive Cranbury, NJ 08512